Understanding the role of HMGN1 in the disproportionate number of DS–ALL patients who are diagnosed with P2RY8::CRLF2 ALL has the potential to lead to novel therapeutic interventions in this high-risk group of patients where effective therapeutic options are currently limited. The gene discussed is HMGN1; the disease is acute lymphoblastic leukemia.